Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Zymeworks Inc.

ZYME · Nasdaq · CIK 0001937653 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

3 Form 4 transaction lines observed in the same window
1 sales · 2 option, withholding, award, gift or other lines

Last qualifying purchase2025-05-19 · EcoR1 Capital, LLC; NODELMAN OLEG · $69.7K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Schayowitz AdamEVP, Head of R&D
○▼
Hollywood MarkEVP & Chief Operating Officer
○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-05-19 · EcoR1 Capital, LLC; NODELMAN OLEG.

Recent Form 4 activity

0Purchases
11Sales
13Other Form 4 lines
11SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING1 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
5,291,136
Previous report
4,939,072
Avg daily volume
953,928
Days to cover
5.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-05-19EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock5,919USD 11.78USD 69,726SEC filing ↗
2025-05-15EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock49,502USD 11.43USD 565,808SEC filing ↗
2025-04-17EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock54,760USD 11.52USD 630,835SEC filing ↗
2025-04-16EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock73,953USD 11.16USD 825,315SEC filing ↗
2025-04-04EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock196,438USD 11.17USD 2,194,212SEC filing ↗
2025-04-03EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock120,770USD 11.84USD 1,429,917SEC filing ↗
2025-04-02EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock74,360USD 11.85USD 881,166SEC filing ↗
2025-04-01EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock48,658USD 11.60USD 564,433SEC filing ↗
2025-03-31EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock4,397USD 11.75USD 51,665SEC filing ↗
2025-03-26EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock43,848USD 12.24USD 536,700SEC filing ↗
2025-03-25EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock53,501USD 12.91USD 690,698SEC filing ↗
2025-03-24EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock22,689USD 13.08USD 296,772SEC filing ↗
2025-03-21EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock31,033USD 12.78USD 396,602SEC filing ↗
2025-03-20EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock73,476USD 12.93USD 950,045SEC filing ↗
2025-03-19EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock58,306USD 12.64USD 736,988SEC filing ↗

Form 4 evidence

24 transaction lines in the latest 365-day window; 106 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-09Schayowitz AdamSale (S)Common Stock13,832USD 25.85USD 357,557SEC filing ↗
2026-10-09Schayowitz AdamOption exercise / conversion (M)Common Stock37,037USD 0.00USD 0SEC filing ↗
2026-07-06Hollywood MarkAward / grant (A)Common Stock939USD 22.22USD 20,865SEC filing ↗
Show recent Form 4 evidence (20 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-09Schayowitz AdamSale (S)Common Stock13,832USD 25.85USD 357,557SEC filing ↗
2026-10-09Schayowitz AdamOption exercise / conversion (M)Common Stock37,037USD 0.00USD 0SEC filing ↗
2026-07-06Hollywood MarkAward / grant (A)Common Stock939USD 22.22USD 20,865SEC filing ↗
2026-01-12Hollywood MarkSale (S)Common Stock6,120USD 22.67USD 138,740SEC filing ↗
2026-01-12Hollywood MarkOption exercise / conversion (M)Common Stock17,666USD 0.00USD 0SEC filing ↗
2026-01-12Smith Jeffrey T LSale (S)Common Stock9,310USD 22.67USD 211,058SEC filing ↗
2026-01-12Smith Jeffrey T LOption exercise / conversion (M)Common Stock17,666USD 0.00USD 0SEC filing ↗
2026-01-12Moore Paul AndrewSale (S)Common Stock9,560USD 22.67USD 216,725SEC filing ↗
2026-01-12Moore Paul AndrewOption exercise / conversion (M)Common Stock17,666USD 0.00USD 0SEC filing ↗
2026-01-12Galbraith KennethSale (S)Common Stock30,424USD 22.67USD 689,712SEC filing ↗
2026-01-12Galbraith KennethOption exercise / conversion (M)Common Stock64,000USD 0.00USD 0SEC filing ↗
2026-01-06PATTERSON LEONE DAward / grant (A)Common Stock459USD 10.55USD 4,842SEC filing ↗
2026-01-05Smith Jeffrey T LSale (S)Common Stock10,538USD 25.10USD 264,504SEC filing ↗
2026-01-05Smith Jeffrey T LOption exercise / conversion (M)Common Stock20,000USD 0.00USD 0SEC filing ↗
2026-01-05Moore Paul AndrewSale (S)Common Stock20,110USD 25.10USD 504,761SEC filing ↗
2026-01-05Moore Paul AndrewOption exercise / conversion (M)Common Stock37,168USD 0.00USD 0SEC filing ↗
2026-01-05Galbraith KennethSale (S)Common Stock54,343USD 25.10USD 1,364,009SEC filing ↗
2026-01-05Galbraith KennethOption exercise / conversion (M)Common Stock114,334USD 0.00USD 0SEC filing ↗
2025-12-22Galbraith KennethSale (S)Common Stock47,528USD 27.02USD 1,284,207SEC filing ↗
2025-12-22Galbraith KennethOption exercise / conversion (M)Common Stock100,000USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerZYME
CIK0001937653
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history106 transaction lines from 2022-10-13 to 2026-10-09
46 P purchase lines · 28 S sale lines · 32 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.